

SAVE THE DATE

Sharing Best Practices to Optimize Patient Care in Lung Cancer in Europe

November 7 and 14, 2022

VIRTUAL MEETING

Monday, November 7, 2022

15.00 – 19.00 CET (Central European Time)

Monday, November 14, 2022

16.00 – 19.00 CET (Central European Time)

REGISTER NOW

This 2-day interactive virtual meeting with global experts will focus on the management of patients with lung cancer in Europe.

DAY 1 Follow presentations on the optimal management of early-stage NSCLC, join a debate on neoadjuvant vs adjuvant therapy, and engage with the faculty in panel discussions

DAY 2 Learn about treatment strategies for patients with metastatic NSCLC and attend patient case-based panel discussion exemplifying these strategies

CHAIRS



Corey J. Langer, MD, FACP
University of Pennsylvania Perelman
School of Medicine, USA



Solange Peters, MD, PhD
University Hospital of Lausanne,
Switzerland



DAY 1 – PLENARY SESSIONS

Monday, November 7, 2022 from 15.00 – 19.00 CET (Central European Time)

(CET)	TITLE	SPEAKER
15.00 – 15.10	Welcome and Meeting Overview	Solange Peters
15.10 – 15.40	Recent Developments in NSCLC – What Is New in Research and Management? <ul style="list-style-type: none"> Overview of recently presented data in NSCLC 	Corey Langer
15.40 – 16.00	Biomarker and Mutational Testing for NSCLC – What, Where, and When? <ul style="list-style-type: none"> NSCLC heterogeneity, overview of current and emerging biomarkers and comutations, and best practices and guidelines for testing at diagnosis and during treatment of NSCLC 	Umberto Malapelle
16.00 – 16.20	Targeted Therapies for Early-Stage NSCLC – Evidence-Based Data and Perspectives <ul style="list-style-type: none"> Summary of targeted therapies for different NSCLC genotypes 	Enriqueta Felip
16.20 – 16.40	Immunotherapy in Resectable NSCLC <ul style="list-style-type: none"> Current standard practices and ongoing studies 	Benjamin Besse
16.40 – 17.10	Tumor Board Discussion <ul style="list-style-type: none"> Local case 1: Resectable NSCLC Local case 2: Unresectable NSCLC Discussion and Q&A 	Moderator: Solange Peters Local case presenter Local case presenter All faculty
17.10 – 17.20	BREAK	
17.20 – 17.40	Neoadjuvant Therapy for NSCLC – Is It Ready for Prime Time? <ul style="list-style-type: none"> Current state of neoadjuvant therapy in resectable vs unresectable NSCLC 	Anne-Marie Dingemans
17.40 – 18.00	Locally Advanced Unresectable NSCLC – What Are the Options? <ul style="list-style-type: none"> Current standard practices and ongoing studies 	Luis Paz-Ares
18.00 – 18.30	Debate: Adjuvant or neoadjuvant therapy for NSCLC? <ul style="list-style-type: none"> Neoadjuvant therapy Adjuvant therapy Discussion and voting 	Moderator: Corey Langer Johan Vansteenkiste Benjamin Besse All faculty
18.30 – 18.50	De Novo – or at relapse – oligometastatic NSCLC: Management of Local and Systemic Disease <ul style="list-style-type: none"> Work-up first recurrence vs de novo oligometastatic NSCLC including sites of involvement (isolated vs systemic recurrence) 	Federico Cappuzzo
18.50 – 19.00	Session Close	Corey Langer



DAY 2: PLENARY SESSIONS

Monday, 14 November 2022 from 16.00 – 19.00 CET (Central European Time)

(CET)	TITLE	SPEAKER
16.00 – 16.10	Session Open	Corey Langer
16.10 – 16.30	Optimizing First-Line Therapy in NSCLC – Integration of Immunotherapy Into Frontline Regimens <ul style="list-style-type: none"> Optimal use of immunotherapeutic treatment choices in frontline NSCLC 	Luis Paz-Ares
16.30 – 16.50	Current Immunotherapy Options for Relapsed NSCLC <ul style="list-style-type: none"> Optimal use of immunotherapeutic treatment choices in relapsed NSCLC including considerations for potential rechallenge, and treatment selection mono vs combination therapy 	Benjamin Besse
16.50 – 17.25	Tumor Board Discussion <ul style="list-style-type: none"> Local case 1: Frontline setting Local case 2: Relapsed setting Discussion & Q&A 	Moderator: Solange Peters Local case presenter Local case presenter All faculty
17.25 – 17.35	BREAK	
17.35 – 17.50	ALK Inhibitors in NSCLC <ul style="list-style-type: none"> Considerations for optimal use in clinical practice in patients with and without brain metastasis 	Enriqueta Felip
17.50 – 18.05	EGFR Inhibitors in NSCLC <ul style="list-style-type: none"> Considerations for optimal use in clinical practice 	Johan Vansteenkiste
18.05 – 18.20	Other Targets in NSCLC <ul style="list-style-type: none"> Considerations for optimal use of ROS1, NTRK, RET and MET inhibitors in clinical practice 	Anne-Marie Dingemans
18.20 – 18.50	Tumor Board Discussion <ul style="list-style-type: none"> Local case 1: ALK inhibitor Local case 2: EGFR inhibitor Discussion & Q&A 	Moderator: Corey Langer Local case presenter Local case presenter All faculty
18.50 – 19.00	Session Close	Solange Peters